Skip to content

The impact of a home-based exercise program on health and fitness in wheelchair users

Influence of a home-based exercise intervention on human health indices in individuals with chronic spinal cord injury (HOMEX-SCI): a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN57096451
Enrollment
24
Registered
2014-07-29
Start date
2014-06-30
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal cord injury (SCI), moderate-intensity exercise, metabolic health, obesity, cardiovascular disease Injury, Occupational Diseases, Poisoning

Interventions

Current interventions as of 01/02/2016: Participants will be randomly assigned to either a 6-week home-based exercise intervention or a control group at a ratio of 2:1, using a minimisation approach a

Sponsors

University of Bath (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Individuals with a chronic SCI (> 12 months post-injury) below T2 or other disabling condition with a similar level of impairment 2. Motor-complete SCI (American Spinal Injury Association scale A or B) 3. Aged between 18 to 65 years 4. Objectively measured physical activity level = 1.6 5. Regular manual wheelchair user (> 70% of ambulation)

Exclusion criteria

Exclusion criteria: 1. Individuals with an acute SCI (< 12 months post-injury) 2. Pregnant women 3. Under 18 years old 4. Cardiovascular contra-indications for testing according to the American College of Sports Medicine (ACSM) 5. Severe musculoskeletal complaints of the upper extremities that contraindicate performance of wheelchair propulsion/arm crank ergometry 6. Individuals with active medical issues; pressure sores, urinary tract infections, or heart disorders 7. Plans to change lifestyle, e.g. diet or physical activity

Design outcomes

Primary

MeasureTime frame
Changes in insulin sensitivity and glycaemic control measured at baseline and at the end of the intervention/control (i.e. after 6 weeks).

Secondary

MeasureTime frame
1. Other blood measurements related to metabolic function and inflammation (e.g. cholesterol, non-esterified fatty acids (NEFA), triacylglycerol, interleukin-6 [IL-6], leptin and adiponectin) 2. Changes in maximal oxygen uptake, peak power and upper body strength 3. Changes in body composition 4. Changes in adipose tissue gene/protein expression related to metabolic function and inflammation 5. Changes in immune competency 6. Changes in quality of life and other psychological variables focussed around self-efficacy, independence and fatigue 7. Changes in physical activity and eating behaviours Measured at baseline and at the end of the intervention (i.e. after 6 weeks)

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 6, 2026